Corvus Pharmaceuticals, Inc. (CRVS) News
Filter CRVS News Items
CRVS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CRVS News Highlights
- CRVS's 30 day story count now stands at 2.
- Over the past 7 days, the trend for CRVS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- CELL are the most mentioned tickers in articles about CRVS.
Latest CRVS News From Around the Web
Below are the latest news stories about CORVUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CRVS as an investment opportunity.
Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 28, 2023Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTBURLINGAME, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on March 28, 2023 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter and full year 2022 financial results. The conference call can be accessed by dialing 1-844-825-9789 or 1-412-317- |
Corvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual MeetingPreclinical data builds on objective tumor responses achieved in the ongoing Phase 1/1b clinical trial of CPI-818 for the treatment of refractory T cell lymphoma and further supports its broad potential across a range of oncology and immune diseasesBURLINGAME, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present new data for CPI-818, the Company’s ITK inhibitor, at the American Ass |
Corvus Pharma's HIV Candidate Shows Potential To Prevent Virus Re-EmergenceCorvus Pharmaceuticals Inc (NASDAQ: CRVS) announced new data demonstrating the potential of CPI-818, an ITK inhibitor, to reduce the need for chronic human immunodeficiency virus (HIV) therapy. For people living with HIV on antiretroviral therapy, HIV can be reduced to levels below detection limits, which enables the restoration and preservation of immune system function, reduces HIV-associated morbidity, and prevents HIV transmission. However, in these individuals, the virus persists in a laten |
'Block-and-lock' HIV path targeted by UCSF professor, Peninsula drug company“This cuts the virus off at its knees," said the co-author of a presentation at the CROI meeting this week. |
Corvus Pharmaceuticals Announces New Data Demonstrating CPI-818’s (ITK Inhibitor) Potential to Block HIV Latency ReversalFindings may provide a treatment that enables discontinuation of HIV antiretroviral therapy by preventing re-emergence of the virus Data to be presented at the Conference on Retroviruses and Opportunistic Infections Research partners from UCSF and Vitalant to continue studying potential for ITK inhibition to be developed within antiproliferative and “block-and-lock” HIV cure strategies BURLINGAME, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NAS |
Quite a few insiders invested in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) last year which is positive news for shareholdersWhen a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase... |
Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & ExpositionResults in patients with refractory T cell lymphoma demonstrated CPI-818’s anti-tumor activity and effects on T cell differentiation which indicate therapeutic potential in Th2 and Th17-mediated autoimmune and allergic diseases Corvus confirms plans to initiate a Phase 2 clinical trial of CPI-818 in T cell lymphoma and a Phase 1 clinical trial in atopic dermatitis, both in 2023 Company to host conference call and webcast today at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif., Dec. 12, 2022 (GLOBE N |
Corvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022Event will focus on CPI-818 (ITK inhibitor) clinical development and will take place at 4:30 pm ET / 1:30 pm PTBURLINGAME, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will host an investor conference call to provide an update on CPI-818 data that will be presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, along with an update |
James Rosenbaum Presented the Distinguished Service Award by the American College of RheumatologyBURLINGAME, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- James T. Rosenbaum, MD, Senior Vice President of Research at Corvus Pharmaceuticals (Nasdaq: CRVS), was presented with the Distinguished Service Award by the American College of Rheumatology (ACR) at its annual meeting in Philadelphia on November 12, 2022. Dr. Rosenbaum received the ACR’s second highest honor, for his outstanding contributions to rheumatology and care of patients. Founded in 1934, the ACR is a not-for-profit, professional ass |
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial ResultsData From CPI-818 T Cell Lymphoma Study Accepted for Presentation at the 64th ASH Annual Meeting and Exposition; Advancing CPI-818 Development for Autoimmune and Allergic Diseases Initiation of a Phase 1b/2 Clinical Trial of Ciforadenant in First Line Renal Cell Cancer (RCC) in Partnership with Kidney Cancer Research Consortium (KCRC) IND approved in China for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., Nov. 03, 20 |